Elite Pharmaceuticals, Inc.
ELTP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -9.7% | 25.7% | 122.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 38.7% | 67.7% | 54.1% | 42.6% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 44.5% | 0.3% | 62.4% | -70.2% |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 37.7% | -14.6% | 53.1% | -75.8% |
| EPS Diluted | 0.01 | -0.006 | 0.016 | -0.01 |
| % Growth | 281.8% | -134.6% | 255.9% | – |
| Operating Cash Flow | $0 | $0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | $0 | $0 | $0 | -$0 |